Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman’s disease
oleh: Hiroshi Kawabata, Naohisa Tomosugi, Junya Kanda, Yasuhiro Tanaka, Kazuyuki Yoshizaki, Takashi Uchiyama
| Format: | Article |
|---|---|
| Diterbitkan: | Ferrata Storti Foundation 2007-06-01 |
Deskripsi
We report two cases of multicentric Castleman’s disease (MCD) whose serum hepcidin levels were rapidly down-regulated by administration of tocilizumab, an anti- interleukin 6 (IL-6) receptor antibody. Our results indicate that IL-6-induced hepcidin over-production may be involved in the pathophysiology of microcytic anemia commonly observed in this disease.